A SARS-CoV-2 Nanobody Displayed on the Surface of Human Ferritin with High Neutralization Activity

References

• Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity, and immunity aspects of pandemic human coronaviruses. Infect Genet Evol. 2020;85. doi:10.1016/j.meegid.2020.104502
   Web of Science ®Google Scholar
• Wrapp D, Wang NS, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–+. doi:10.1126/science.abb2507
   PubMed Web of Science ®Google Scholar
• Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. Nanomedicine. 2013;8(6):1013–1026. doi:10.2217/Nnm.13.86
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–448. doi:10.1038/363446a0
   PubMed Web of Science ®Google Scholar
• Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01603
   PubMed Web of Science ®Google Scholar
• Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Invest Dr. 2009;10(11):1212–1224.
   PubMed Web of Science ®Google Scholar
• Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discovery Today. 2016;21(7):1076–1113. doi:10.1016/j.drudis.2016.04.003
   PubMed Web of Science ®Google Scholar
• Hanke L, Perez LV, Sheward DJ, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun. 2020;11(1). doi:10.1038/s41467-020-18174-5
   Web of Science ®Google Scholar
• Huo J, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846–854. doi:10.1038/s41594-020-0469-6
   PubMed Web of Science ®Google Scholar
• Fan K, Jiang B, Guan Z, et al. Fenobody: a ferritin-displayed nanobody with high apparent affinity and half-life extension. Anal Chem. 2018;90(9):5671–5677. doi:10.1021/acs.analchem.7b05217
   PubMed Web of Science ®Google Scholar
• Powell AE, Zhang KM, Sanyal M, et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. Acs Central Sci. 2021;7(1):183–199. doi:10.1021/acscentsci.0c01405
   PubMed Web of Science ®Google Scholar
• Cho KJ, Shin HJ, Lee JH, et al. The crystal structure of ferritin from reveals unusual conformational changes for iron uptake. J Mol Biol. 2009;390(1):83–98. doi:10.1016/j.jmb.2009.04.078
   PubMed Web of Science ®Google Scholar
• Han JA, Kang YJ, Shin C, et al. Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development. Nanomed Nanotechnol. 2014;10(3):561–569. doi:10.1016/j.nano.2013.11.003
   PubMed Web of Science ®Google Scholar
• Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99(10):3505–3516. doi:10.1182/blood.V99.10.3505
   PubMed Web of Science ®Google Scholar
• Harrison PM, Arosio P. Ferritins: molecular properties, iron storage function and cellular regulation. BBA-Bioenergetics. 1996;1275(3):161–203. doi:10.1016/0005-2728(96)00022-9
   Google Scholar
• Felberbaum RS. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J. 2015;10(5):702–785. doi:10.1002/biot.201400438
   PubMed Web of Science ®Google Scholar
• van Oosten L, Altenburg JJ, Fougeroux C, et al. Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants. Mbio. 2021;12(5). doi:10.1128/mBio.01813-21
   PubMed Web of Science ®Google Scholar
• Geisler C, Mabashi-Asazuma H, Jarvis DL. An overview and history of glyco-engineering in insect expression systems. Methods Mol Biol. 2015;1321:131–152. doi:10.1007/978-1-4939-2760-9_10
   PubMedGoogle Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–+. doi:10.1038/s41586-021-03819-2
   PubMed Web of Science ®Google Scholar
• Liu XJ, Yang X, Mehboob A, et al. A construction strategy for a baculovirus-silkworm multigene expression system and its application for coexpression of type I and type II interferons. Microbiologyopen. 2020;9(3):e979. doi:10.1002/mbo3.979
   PubMed Web of Science ®Google Scholar
• Liu XJ, Wei YL, Li YN, et al. A highly efficient and simple construction strategy for producing recombinant baculovirus nucleopolyhedrovirus. PLoS One. 2016;11(3). doi:10.1371/journal.pone.0152140
   Web of Science ®Google Scholar
• Hu J, Gao QZ, He CL, Huang AL, Tang N, Wang K. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 2020;7(4):551–557. doi:10.1016/j.gendis.2020.07.006
   PubMed Web of Science ®Google Scholar
• Wu CH, Xu Q, Wang HY, et al. Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles. Acta Pharmaceutica Sinica B. 2022;12(3):1523–1533. doi:10.1016/j.apsb.2021.09.004
   PubMed Web of Science ®Google Scholar
• Van Heeke G, Allosery K, De Brabandere V, De Smedt T, Detalle L, de Fougerolles A. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacol Therapeut. 2017;169:47–56. doi:10.1016/j.pharmthera.2016.06.012
   PubMed Web of Science ®Google Scholar
• Luiz MB, Pereira SS, Prado NDR, et al. Camelid Single-Domain Antibodies (VHHs) against crotoxin: a basis for developing modular building blocks for the enhancement of treatment or diagnosis of crotalic envenoming. Toxins. 2018;10(4). doi:10.3390/toxins10040142
   PubMed Web of Science ®Google Scholar
• Roovers RC, Vosjan MJWD, Laeremans T, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011;129(8):2013–2024. doi:10.1002/ijc.26145
   PubMed Web of Science ®Google Scholar
• Deckers N, Saerens D, Kanobana K, et al. Nanobodies, a promising tool for species-specific diagnosis of cysticercosis. Int J Parasitol. 2009;39(5):625–633. doi:10.1016/j.ijpara.2008.10.012
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou X, Bian Y, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nature Nanotechnol. 2020;15(5):406–416. doi:10.1038/s41565-020-0648-y
   PubMed Web of Science ®Google Scholar
• López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotec. 2016;14:58–68. doi:10.1016/j.csbj.2015.11.001
   PubMed Web of Science ®Google Scholar
• Li D, Song HZ, Li JL, et al. Expression and evaluation of a novel PPRV nanoparticle antigen based on ferritin self-assembling technology. Pharmaceutics. 2022;14(9). doi:10.3390/pharmaceutics14091902
   Web of Science ®Google Scholar
• Usami A, Suzuki T, Nagaya H, Kaki H, Ishiyama S. Silkworm as a Host of Baculovirus Expression. Curr Pharm Biotechno. 2010;11(3):246–250. doi:10.2174/138920110791112013
   PubMed Web of Science ®Google Scholar
• Usami A, Ishiyama S, Enomoto C, et al. Comparison of recombinant protein expression in a baculovirus system in insect cells (Sf9) and silkworm. J Biochemi. 2011;149(2):219–227. doi:10.1093/jb/mvq138
   PubMed Web of Science ®Google Scholar